Kornitzer Capital Management Inc. KS Raises Holdings in Personalis (NASDAQ:PSNL)

Kornitzer Capital Management Inc. KS raised its holdings in shares of Personalis (NASDAQ:PSNL) by 12.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 279,960 shares of the company’s stock after purchasing an additional 31,330 shares during the period. Kornitzer Capital Management Inc. KS owned approximately 0.90% of Personalis worth $4,108,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PSNL. Strs Ohio purchased a new stake in Personalis during the 3rd quarter valued at $33,000. Point72 Hong Kong Ltd purchased a new stake in Personalis during the 2nd quarter valued at $109,000. Cubist Systematic Strategies LLC purchased a new stake in Personalis during the 2nd quarter valued at $177,000. SG Americas Securities LLC purchased a new stake in Personalis during the 2nd quarter valued at $228,000. Finally, Northern Trust Corp purchased a new stake in Personalis during the 2nd quarter valued at $352,000. Institutional investors and hedge funds own 50.35% of the company’s stock.

Shares of PSNL stock traded up $0.29 on Friday, reaching $10.46. The stock had a trading volume of 185,500 shares, compared to its average volume of 355,310. Personalis has a 1 year low of $9.65 and a 1 year high of $31.88. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.13 and a quick ratio of 3.06. The stock’s 50 day simple moving average is $12.46.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, August 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.58). The firm had revenue of $15.80 million during the quarter, compared to analysts’ expectations of $14.92 million. The company’s revenue was up 79.5% compared to the same quarter last year. As a group, analysts expect that Personalis will post -0.92 earnings per share for the current year.

A number of equities analysts have recently issued reports on PSNL shares. Bank of America upgraded Personalis from a “neutral” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Thursday, September 26th. Morgan Stanley started coverage on Personalis in a research note on Monday, July 15th. They issued an “overweight” rating and a $28.00 price target on the stock. Cowen started coverage on Personalis in a research note on Monday, July 15th. They issued an “outperform” rating on the stock. CIBC started coverage on Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 price target on the stock. Finally, Oppenheimer started coverage on Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 price target on the stock. Six analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $24.20.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Further Reading: What does the Dogs of the Dow mean?

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis (NASDAQ:PSNL).

Institutional Ownership by Quarter for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply